1-嘧啶-1,4-二氮杂庚烷 | 21279-57-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-嘧啶-1,4-二氮杂庚烷
• 中文别名: 1-(2-嘧啶基)-1,4-二氮杂环庚烷；1-(2-嘧啶基)高哌嗪；1-嘧啶-2-基-[1,4]二氮杂环庚烷
• 英文名称: 1-(2-Pyrimidinyl)homopiperazine
• 英文别名: 1-pyrimidin-2-yl-[1,4]diazepane；1-(2-pyrimidinyl)-1,4-diazepane；1-(2-pyrimidyl)-homopiperazine；1-(2-pyrimidyl)homopiperazine；1-(2-Pyrimidyl)-homopiperazin；1-Pyrimidin-2-yl-1,4-diazepane
• CAS: 21279-57-2
• 化学式: C₉H₁₄N₄
• mdl: MFCD06738258
• 分子量: 178.237
• InChiKey: LZOGPVCTSDAYIP-UHFFFAOYSA-N

物化性质

• 沸点：
  341.5±52.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  8
• 海关编码：
  2933990090
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  1-嘧啶-1,4-二氮杂庚烷 在 盐酸羟胺 、 碳酸氢钠 、 potassium iodide 、 potassium hydroxide 作用下， 以 乙醇 、 异丙醇 为溶剂， 反应 17.0h， 生成 1-(4-fluorophenyl)-4-(4-(pyrimidin-2-yl)-1,4-diazepan-1-yl)butan-1-one oxime
  参考文献：
  名称：

  SYA 013 analogs as moderately selective sigma-2 (σ2) ligands: Structure-affinity relationship studies

  摘要：

  Several lines of evidence suggest that selective sigma-2 (sigma(2)) ligands might be useful for the treatment of solid tumors. However, very few selective sigma(2) ligands have been identified. This study was aimed at identifying new selective sigma(2) receptor ligands using a previously identified agent, SYA 013 as a lead. Four groups, homopiperazine, piperazine, tropane and selected oxime analogs of the homopiperazines were identified, synthesized and subsequently screened at the sigma(1) and sigma(2) receptors. The results demonstrate that these scaffolds can be modified to obtain selective sigma(2) receptor ligands. 1-(5-Chloropyridin-2-yl)-4-(3-((4-fluorophenyl)thio)propyl)-1,4-diazepane, 7 and 3-(4-chlorophenyl)-8-(3-((2-fluorophenyl)thio)propyl)-8-azabicyclo[ 3.2.1]octan-3-ol, 21 were identified as the highest binding affinity ligands (sigma(2)Ki = 2.2 nM) and (4-(4-(5-chloropyridin-2-yl)-1,4-diazepan-1-yl)-1-(4-fluorophenyl)-butan-1-one oxime, 22 as a high affinity and the most selective ligand for the sigma(2) receptor (sigma(1)Ki/sigma(2)Ki = 41.8).

  DOI：

  10.1016/j.bmc.2019.01.035
• 作为产物：
  描述：

  tert-butyl 4-(pyrimidin-2-yl)-1,4-diazepan-1-carboxylate 在 盐酸 、 水 作用下， 以 乙酸乙酯 为溶剂， 反应 12.0h， 生成 1-嘧啶-1,4-二氮杂庚烷
  参考文献：
  名称：

  Synthesis and biological evaluation of homopiperazine derivatives with β-aminoacyl group as dipeptidyl peptidase IV inhibitors

  摘要：

  Compounds with homopiperazine skeleton are designed to find a potent DPP-IV inhibitor without inhibiting CYP. Thus a series of beta-aminoacyl-containing homopiperazine derivatives was synthesized and evaluated. Compounds with acid moiety were found to be potent inhibitors of DPP-IV without inhibiting CYP 3A4. More specifically, compound 7m showed nanomolar activity with no inhibition towards five subtypes of CYPs, was considered as a prototype for further derivatization. Based on its X-ray co-crystal structure with human DPP-IV, we identified compounds 7s and 7t which showed good in vitro activity, no CYP inhibition, and good selectivity.

  DOI：

  10.1016/j.bmcl.2008.10.076

文献信息

• Synthesis and Anxiolytic Activity of N-Substituted Cyclic Imides(1R*,2S*,3R*,4S*)-N-(4-(4-(2-Pyrimidinyl)-1-piperazinyl)butyl)-2,3-bicyclo(2.2.1)heptanedicarboximide(Tandospirone) and Related Compounds.
  作者：Kikuo ISHIZUMI、Atsuyuki KOJIMA、Fujio ANTOKU

  DOI：10.1248/cpb.39.2288

  日期：——

  The in vitro binding affinities of these compounds were also examined for 5-HT1A receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, (1R*,2S*,-3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (1: tandospirone), was found to be equipotent with buspirone in its anxiolytic activity and more anxio-selective

  合成了一系列带有ω-（4-芳基和4-杂芳基-1-哌嗪基）烷基的环状酰亚胺，并在体内测试其抗焦虑活性。还检查了这些化合物的体外结合亲和力的5-HT1A受体位点。讨论了这些系列中的构效关系。这些化合物之一，（1R *，2S *，-3R *，4S *）-N- [4- [4-（4-嘧啶基）-1-哌嗪基]丁基] -2,3-双环[2.2.1已发现]庚烷二甲酰亚胺（1：tandospirone）与丁螺环酮具有相同的抗焦虑活性，并且比丁螺环酮和地西epa具有更高的选择性。Tandospirone（1）目前正在作为一种选择性抗焦虑药进行临床评估。
• Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
  申请人：Bono Francoise

  公开号：US20050176722A1

  公开（公告）日：2005-08-11

  The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R 1 represents a halogen atom; a trifluoromethyl radical; a (C 1 -C 4 )alkyl; a (C 1 -C 4 )alkoxy; a trifluoromethoxy radical; R 2 represents a hydrogen atom or a halogen atom; R 3 represents a hydrogen atom; a group —OR 5 ; a group —CH 2 OR 5 ; a group —NR 6 R 7 ; a group —NR 8 COR 9 ; a group —NR 8 CONR 10 R 11 ; a group —CH 2 NR 12 R 13 ; a group —CH 2 NR 8 CONR 14 R 15 ; a (C 1 -C 4 )alkoxycarbonyl; a group —CONR 16 R 17 ; or else R 3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R 4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C 1 -C 4 )alkyl; a (C 1 -C 4 )alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

  该发明涉及一般式(I)的取代1-哌嗪基酰基哌啶衍生物，其中：n为1或2；p为1或2；R1代表卤原子；三氟甲基基团；(C1-C4)烷基；(C1-C4)烷氧基；三氟甲氧基基团；R2代表氢原子或卤原子；R3代表氢原子；—OR5基团；—CH2OR5基团；—NR6R7基团；—NR8COR9基团；—NR8CONR10R11基团；—CH2NR12R13基团；—CH2NR8CONR14R15基团；(C1-C4)烷氧羰基；—CONR16R17基团；或者R3构成与其连接的碳原子和哌啶环的相邻碳原子之间的双键；R4代表从中选择的芳香族基：所述芳香族基未取代或者经过单取代或双取代，取代基独立选择自卤原子；(C1-C4)烷基；(C1-C4)烷氧基；三氟甲基基团；制备方法和治疗应用。
• REMEDIES OR PREVENTIVES FOR AIDS
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0878194A1

  公开（公告）日：1998-11-18

  The present invention is to provide the combined use of one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor, and an AIDS therapeutic agent or preventive agent containing as its active ingredients one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor.

  本发明提供了一种或两种或两种以上具有抗HIV活性的喹诺酮羧酸与一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的联合使用，以及一种包含作为其活性成分的抗HIV活性的喹诺酮羧酸和一种或两种或两种以上的逆转录酶抑制剂或HIV蛋白酶抑制剂的艾滋病治疗剂或预防剂。
• Multicyclic compounds and methods of their use
  申请人：Barbosa Joseph

  公开号：US20060258672A1

  公开（公告）日：2006-11-16

  This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use in, for example, the treatment of cognitive disorders.

  这项发明涉及多环化合物，包括它们的药物组合物，以及它们在治疗认知障碍等方面的使用方法。
• [EN] THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS PYRIDYLES SUBSTITUÉS PAR THIAZOLYL OU THIADIAZOLYL UTILES EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013106641A1

  公开（公告）日：2013-07-18

  Compounds having the following formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C-R7, are useful as kinase modulators, including IRAK-4 modulation.

  具有以下公式(I)或其对应的手性异构体、对映异构体或药用可接受盐的化合物，其中X是N或C-R7，可用作激酶调节剂，包括IRAK-4调节。